News | April 28, 2025
Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Zydus MedTech gets rights to market the innovative Transcatheter Aortic Valve Implantation (TAVI) technology in India, Europe and other select markets
The merged entity ‘Aster DM Quality Care’ will be jointly controlled by Aster Promoters and Blackstone
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
The unique soap-fusion of Gondhoraj lime and neem provides a refreshing skin-friendly experience
Subscribe To Our Newsletter & Stay Updated
